Annual Cash & Cash Equivalents
$68.83 M
+$2.49 M+3.76%
31 December 2023
Summary:
Silence Therapeutics annual cash & cash equivalents is currently $68.83 million, with the most recent change of +$2.49 million (+3.76%) on 31 December 2023. During the last 3 years, it has risen by +$31.42 million (+84.00%). SLN annual cash & cash equivalents is now -30.65% below its all-time high of $99.25 million, reached on 31 December 2021.SLN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$82.91 M
-$55.57 M-40.13%
01 September 2024
Summary:
Silence Therapeutics quarterly cash and cash equivalents is currently $82.91 million, with the most recent change of -$55.57 million (-40.13%) on 01 September 2024. Over the past year, it has increased by +$11.15 million (+15.54%). SLN quarterly cash and cash equivalents is now -41.92% below its all-time high of $142.73 million, reached on 31 March 2024.SLN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SLN Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3.8% | +15.5% |
| 3 y3 years | +84.0% | -13.6% |
| 5 y5 years | +152.4% | +367.9% |
SLN Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -30.6% | +84.0% | -41.9% | +121.2% |
| 5 y | 5 years | -30.6% | +288.4% | -41.9% | +552.5% |
| alltime | all time | -30.6% | +3663.5% | -41.9% | +5524.6% |
Silence Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $82.91 M(-40.1%) |
| June 2024 | - | $138.47 M(-3.0%) |
| Mar 2024 | - | $142.73 M(+107.4%) |
| Dec 2023 | $68.83 M(+3.8%) | $68.83 M(-4.1%) |
| Sept 2023 | - | $71.76 M(+91.4%) |
| June 2023 | - | $37.49 M(-35.2%) |
| Mar 2023 | - | $57.88 M(-12.8%) |
| Dec 2022 | $66.34 M(-33.2%) | $66.34 M(-34.0%) |
| Sept 2022 | - | $100.52 M(+60.7%) |
| June 2022 | - | $62.54 M(-19.7%) |
| Mar 2022 | - | $77.89 M(-21.5%) |
| Dec 2021 | $99.25 M(+165.3%) | $99.25 M(+3.4%) |
| Sept 2021 | - | $95.96 M(-2.7%) |
| June 2021 | - | $98.59 M(+163.6%) |
| Dec 2020 | $37.41 M(+111.1%) | $37.41 M(+194.4%) |
| June 2020 | - | $12.71 M(-28.3%) |
| Dec 2019 | $17.72 M(-35.0%) | - |
| Dec 2019 | - | $17.72 M(+21.5%) |
| June 2019 | - | $14.59 M(-46.5%) |
| Dec 2018 | $27.27 M(-52.8%) | - |
| Dec 2018 | - | $27.27 M(-28.9%) |
| June 2018 | - | $38.35 M(-33.6%) |
| Dec 2017 | $57.77 M(+20.5%) | - |
| Dec 2017 | - | $57.77 M(+48.7%) |
| June 2017 | - | $38.83 M(-19.0%) |
| Dec 2016 | $47.93 M(-37.7%) | - |
| Dec 2016 | - | $47.93 M(-25.2%) |
| June 2016 | - | $64.07 M(-16.7%) |
| Dec 2015 | $76.90 M(+193.1%) | - |
| Dec 2015 | - | $76.90 M(-12.3%) |
| June 2015 | - | $87.70 M(+234.2%) |
| Dec 2014 | $26.24 M(+0.1%) | - |
| Dec 2014 | - | $26.24 M(-27.7%) |
| June 2014 | - | $36.28 M(+38.5%) |
| Dec 2013 | $26.20 M(+82.0%) | - |
| Dec 2013 | - | $26.20 M(-12.9%) |
| June 2013 | - | $30.08 M |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $14.40 M(+153.4%) | - |
| Dec 2012 | - | $14.40 M(+876.7%) |
| June 2012 | - | $1.47 M(-74.1%) |
| Dec 2011 | $5.68 M(+3.2%) | - |
| Dec 2011 | - | $5.68 M(-45.5%) |
| June 2011 | - | $10.42 M(+89.4%) |
| Dec 2010 | $5.50 M(+200.9%) | - |
| Dec 2010 | - | $5.50 M(-46.1%) |
| June 2010 | - | $10.21 M(+458.5%) |
| Dec 2009 | $1.83 M(-62.7%) | - |
| Dec 2009 | - | $1.83 M(-63.7%) |
| June 2009 | - | $5.03 M(+2.6%) |
| Dec 2008 | $4.91 M(-75.7%) | - |
| Dec 2008 | - | $4.91 M(-56.5%) |
| June 2008 | - | $11.28 M(-44.2%) |
| Dec 2007 | $20.21 M(+16.9%) | - |
| Dec 2007 | - | $20.21 M(+57.1%) |
| June 2007 | - | $12.86 M(-25.6%) |
| Dec 2006 | $17.28 M(+10.5%) | - |
| Dec 2006 | - | $17.28 M(+37.5%) |
| June 2006 | - | $12.57 M(-19.6%) |
| Dec 2005 | $15.63 M(+209.5%) | - |
| Dec 2005 | - | $15.63 M(+397.7%) |
| June 2005 | - | $3.14 M(-37.8%) |
| Dec 2004 | $5.05 M(-44.5%) | - |
| Dec 2004 | - | $5.05 M(-29.0%) |
| June 2004 | - | $7.11 M(-21.9%) |
| Dec 2003 | $9.11 M(-21.1%) | - |
| Dec 2003 | - | $9.11 M(-14.1%) |
| June 2003 | - | $10.60 M |
| Dec 2002 | $11.54 M(-12.2%) | - |
| Dec 2001 | $13.14 M(-22.8%) | - |
| Dec 2000 | $17.03 M(+0.1%) | - |
| Dec 1999 | $17.01 M(+180.9%) | - |
| Dec 1998 | $6.05 M(-29.5%) | - |
| Dec 1997 | $8.58 M(-24.7%) | - |
| Dec 1996 | $11.39 M(+485.7%) | - |
| Dec 1995 | $1.95 M | - |
FAQ
- What is Silence Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Silence Therapeutics?
- What is Silence Therapeutics annual cash & cash equivalents year-on-year change?
- What is Silence Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Silence Therapeutics?
- What is Silence Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Silence Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SLN is $68.83 M
What is the all time high annual cash & cash equivalents for Silence Therapeutics?
Silence Therapeutics all-time high annual cash & cash equivalents is $99.25 M
What is Silence Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SLN annual cash & cash equivalents has changed by +$2.49 M (+3.76%)
What is Silence Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SLN is $82.91 M
What is the all time high quarterly cash and cash equivalents for Silence Therapeutics?
Silence Therapeutics all-time high quarterly cash and cash equivalents is $142.73 M
What is Silence Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SLN quarterly cash and cash equivalents has changed by +$11.15 M (+15.54%)